1. Home
  2. CGEM vs ORIC Comparison

CGEM vs ORIC Comparison

Compare CGEM & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$16.13

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo Oric Pharmaceuticals Inc.

ORIC

Oric Pharmaceuticals Inc.

HOLD

Current Price

$8.51

Market Cap

861.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
ORIC
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
861.3M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
CGEM
ORIC
Price
$16.13
$8.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
13
Target Price
$30.13
$19.73
AVG Volume (30 Days)
956.5K
1.0M
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
19.67
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$7.23
52 Week High
$16.74
$14.93

Technical Indicators

Market Signals
Indicator
CGEM
ORIC
Relative Strength Index (RSI) 62.01 39.95
Support Level $11.92 $7.83
Resistance Level N/A $11.22
Average True Range (ATR) 1.03 0.43
MACD 0.08 0.07
Stochastic Oscillator 89.05 48.22

Price Performance

Historical Comparison
CGEM
ORIC

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About ORIC Oric Pharmaceuticals Inc.

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Share on Social Networks: